Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270463 · ClinicalTrials.gov registry record · Phase 1
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
A Phase 1 study, sponsored by Stemline Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02270463 is a Phase 1 study that was terminated before completion, run by Stemline Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT02270463, a Phase 1 study, was terminated before completion, sponsored by Stemline Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401 at the MTD.
Interventions
- DRUG Tagraxofusp-erzs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-02 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02270463
The ClinicalTrials.gov registry entry for NCT02270463 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tagraxofusp-erzs is the first listed.
NCT02270463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02270463 about?
NCT02270463 is a clinical study titled "SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission". This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401 at the MTD.
What is the current status of trial NCT02270463?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-02. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02270463?
The interventions under investigation include: Tagraxofusp-erzs (DRUG).
Who is sponsoring clinical trial NCT02270463?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.